{"id":"177lu-psma-i-t","safety":{"commonSideEffects":[{"rate":null,"effect":"Hematologic toxicity (anemia, thrombocytopenia, leukopenia)"},{"rate":null,"effect":"Xerostomia (dry mouth)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Kidney toxicity"}]},"_chembl":{"chemblId":"CHEMBL3707297","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug combines a lutetium-177 radioisotope with a PSMA-targeting ligand that specifically recognizes and binds to PSMA expressed on prostate cancer cells. Once bound, the radioisotope delivers localized beta radiation directly to PSMA-positive tumors while sparing healthy tissue, enabling targeted internal radiation therapy for metastatic castration-resistant prostate cancer.","oneSentence":"177Lu-PSMA-I&T is a radioligand therapy that binds to prostate-specific membrane antigen (PSMA) on cancer cells and delivers targeted radiation to kill them.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:44.566Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression"}]},"trialDetails":[{"nctId":"NCT07441837","phase":"PHASE2","title":"Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients","status":"NOT_YET_RECRUITING","sponsor":"Ankara University","startDate":"2026-07-01","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT04647526","phase":"PHASE3","title":"Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company","startDate":"2021-02-25","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":455},{"nctId":"NCT07316686","phase":"PHASE1","title":"Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2026-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":18},{"nctId":"NCT05867615","phase":"PHASE2","title":"Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2023-05-25","conditions":"Cancer","enrollment":83},{"nctId":"NCT05893381","phase":"PHASE2","title":"Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2023-06-27","conditions":"Prostate Cancer","enrollment":70},{"nctId":"NCT06361810","phase":"PHASE1, PHASE2","title":"PSMA Therapy and Immunotherapy in Kidney Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-10-01","conditions":"Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma","enrollment":""},{"nctId":"NCT05204927","phase":"PHASE3","title":"177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Curium US LLC","startDate":"2022-02-14","conditions":"Metastasis From Malignant Tumor of Prostate","enrollment":439},{"nctId":"NCT07090369","phase":"PHASE1","title":"Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2025-11-01","conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":20},{"nctId":"NCT05560659","phase":"PHASE2","title":"Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy","status":"RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2023-12-14","conditions":"Oligometastatic Prostate Cancer","enrollment":92},{"nctId":"NCT04886986","phase":"PHASE1, PHASE2","title":"Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer","status":"SUSPENDED","sponsor":"Weill Medical College of Cornell University","startDate":"2021-06-30","conditions":"Prostate Cancer","enrollment":48},{"nctId":"NCT05644080","phase":"NA","title":"68Ga/177Lu-PSMA Theranostics in Recurrent Grade 3 and Grade 4 Glioma","status":"RECRUITING","sponsor":"St. Olavs Hospital","startDate":"2023-03-28","conditions":"High Grade Glioma","enrollment":10},{"nctId":"NCT05496959","phase":"PHASE2","title":"177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2022-09-02","conditions":"Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma","enrollment":93},{"nctId":"NCT05896371","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy","status":"NOT_YET_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2028-03","conditions":"Cancer, Prostate Cancer, Metastatic Cancer","enrollment":500},{"nctId":"NCT04597411","phase":"PHASE1","title":"Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer","status":"RECRUITING","sponsor":"Endocyte","startDate":"2021-04-01","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":99},{"nctId":"NCT06830408","phase":"","title":"Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-07-06","conditions":"mCRPC","enrollment":250},{"nctId":"NCT05383079","phase":"PHASE1, PHASE2","title":"Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2022-09-13","conditions":"Metastatic Castration-resistant Prostate Cancer, MCRPC, Prostate Cancer","enrollment":36},{"nctId":"NCT06343038","phase":"PHASE1","title":"Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2024-02-20","conditions":"Castration-resistant Prostate Cancer","enrollment":25},{"nctId":"NCT06259123","phase":"PHASE2","title":"Neoadjuvant PSMA-RLT in Oligometastatic PCa","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-02-01","conditions":"Prostate Cancer","enrollment":10},{"nctId":"NCT06220188","phase":"PHASE2","title":"PSMA-RLT in Biochemically Recurrent PCa","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-01-15","conditions":"Prostate Cancer Recurrent","enrollment":20},{"nctId":"NCT04291300","phase":"PHASE2","title":"Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2020-05-26","conditions":"Salivary Gland Cancer, Salivary Duct Carcinoma, Adenoid Cystic Carcinoma","enrollment":12},{"nctId":"NCT04297410","phase":"NA","title":"177Lu-PSMA-I&T Prior to Radical Prostatectomy for Locally Advanced Disease","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2019-11-20","conditions":"Prostate Cancer","enrollment":5},{"nctId":"NCT04188587","phase":"PHASE2","title":"177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2019-01-01","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["177Lu-PNT2002"],"phase":"phase_3","status":"active","brandName":"177Lu-PSMA-I&T","genericName":"177Lu-PSMA-I&T","companyName":"Weill Medical College of Cornell University","companyId":"weill-medical-college-of-cornell-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"177Lu-PSMA-I&T is a radioligand therapy that binds to prostate-specific membrane antigen (PSMA) on cancer cells and delivers targeted radiation to kill them. Used for Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}